B. Riley Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Positive 82.7%

Neg 0% Neu 0% Pos 82.7%

B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $37 to $45.